Partnership Introduction
Pentec Health, Inc., a prominent provider of complex care solutions, is significantly expanding its service offerings. The company's latest initiative focuses on the introduction of prescription digital therapeutic services through its newly formed division, Pentec Home Medical. This innovative division aims to meet the unique challenges faced by patients with chronic and rare diseases, particularly in underserved regions.
About Digital Therapeutics
Prescription digital therapeutics (PDTs) are cutting-edge software applications designed for the medical treatment of various conditions. These medically validated interventions aim to improve the health outcomes of patients by utilizing technology in a therapeutic manner. By incorporating PDTs, companies like Pentec Health strive to enhance patient care by offering comprehensive treatment solutions beyond conventional methods.
The Significance of the Partnership
In a strategic move to broaden its impact, Pentec Health has partnered with Luminopia, Inc. This digital health company is at the forefront of developing unique therapies for neuro-visual disorders. This collaboration between Pentec and Luminopia highlights their shared commitment to ensuring that all patients have access to critical treatments.
Products and Services Offered
Luminopia has developed an innovative product known as Luminopia, which has garnered FDA approval. This pioneering digital therapeutic targets amblyopia, often referred to as 'lazy eye,' which is the leading cause of vision impairment in children. The therapy utilizes virtual reality technology combined with engaging visual content to create an immersive treatment experience that aims to enhance visual acuity.
Supporting Patients and Providers
Pentec Health will serve as a vital distribution and service provider for Luminopia. The partnership includes comprehensive support services to guide both patients and healthcare providers. This support encompasses navigating insurance complexities to ensure coverage for the necessary treatments and facilitating patient adherence to achieve favorable health outcomes.
CEO Insights on the Partnership
Matthew Deans, CEO of Pentec Health, expressed excitement about the partnership, stating that their goal is to innovate and streamline care for complex patient needs. He emphasized that this collaboration not only allows them to provide groundbreaking FDA-approved vision therapy but also supports their mission of expanding access to healthcare solutions for more families.
Luminopia's Perspective
Scott Xiao, CEO of Luminopia, also voiced enthusiasm about collaborating with Pentec Health. He emphasized how Pentec's substantial expertise in clinical coordination and patient-centered care will create a positive experience for those in need of Luminopia's therapeutic solutions. This partnership aims to facilitate easier access to essential treatments and navigate the challenges presented by medical benefits.
About the Companies
Pentec Health is a leading name in specialty pharmacy and infusion services, dedicated to addressing the complexities of patient care. The company, which is accredited by the Joint Commission, focuses on providing tailored care solutions that ease the challenges faced by patients with complex conditions. With a strong team of over 350 clinicians, Pentec Health aims to enhance patient outcomes while minimizing administrative burdens.
About Luminopia, Inc. Specializing in neuro-visual disorders, Luminopia is making strides with its innovative software-based therapeutics. The company is committed to rigorous evaluation for FDA approval while ensuring that their products engage patients effectively. They aim to improve vision health, particularly for children with amblyopia.
Usage Indications for Luminopia
Luminopia is a unique digital therapeutic intended for use in conjunction with head-mounted displays (HMDs). It is specifically designed to improve visual acuity in children aged 4-7 diagnosed with amblyopia and associated conditions. Luminopia is recommended as an adjunct to full-time refractive correction measures, such as glasses, and it should be administered under the guidance of qualified eye care professionals. Notably, Luminopia is only available via prescription and is intended for use in home settings.
Frequently Asked Questions
What is the objective of Pentec's partnership with Luminopia?
The partnership aims to expand access to Luminopia's innovative digital therapeutic solutions for patients with vision disorders, particularly children suffering from amblyopia.
What is a prescription digital therapeutic (PDT)?
PDTs are FDA-cleared software applications designed to provide therapeutic interventions for various medical conditions, enhancing health outcomes through technology-based treatments.
How does Luminopia's therapy work?
Luminopia utilizes virtual reality technology to provide a therapeutic, immersive experience that targets visual improvement in children diagnosed with amblyopia.
What support will Pentec Health offer to patients?
Pentec Health will provide navigation support for insurance coverage, ensuring patients can access necessary treatments, along with comprehensive clinical support.
Who can use Luminopia's digital therapeutic?
Luminopia is intended for children aged 4-7 with amblyopia, particularly those experiencing related visual impairments, and it must be prescribed by an eye care professional.
